 RANK Ligand
"RANK Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.
| Descriptor ID |
D053245
|
| MeSH Number(s) |
D12.644.276.374.750.562 D12.776.467.374.750.562 D23.529.374.750.562
|
| Concept/Terms |
RANK Ligand- RANK Ligand
- OPGL Protein
- Osteoclast Differentiation Factor
- Differentiation Factor, Osteoclast
- Osteoprotegerin Ligand
- Receptor Activator of Nuclear Factor-kappa B Ligand
- Receptor Activator of Nuclear Factor kappa B Ligand
- Receptor Activator of Nuclear Factor-kappaB Ligand
- Receptor Activator of Nuclear Factor kappaB Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 11
- TNF Superfamily, Member 11
- RANKL Protein
- Tumor Necrosis Factor-Related Activation-Induced Cytokine
- Tumor Necrosis Factor Related Activation Induced Cytokine
- CD254 Antigen
- Antigen, CD254
- TRANCE Protein
|
Below are MeSH descriptors whose meaning is more general than "RANK Ligand".
Below are MeSH descriptors whose meaning is more specific than "RANK Ligand".
This graph shows the total number of publications written about "RANK Ligand" by people in this website by year, and whether "RANK Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 3 | 1 | 4 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 1 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2015 | 1 | 2 | 3 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "RANK Ligand" by people in Profiles.
-
Payne KA, Shaw NM, Erickson CB, Yarger P, Yu Y, Baldini T, Kleck CJ, Patel VV, Burger EL. Blockade of Osteoclast-Mediated Bone Resorption With a RANKL-Inhibitor Enhances Bone Formation in a Rat Spinal Fusion Model. Spine (Phila Pa 1976). 2022 Aug 15; 47(16):1165-1171.
-
Wu W, Song K, Chen G, Liu N, Cao T. Ganoderic acid A improves osteoarthritis by regulating RANKL/OPG ratio. Chem Biol Drug Des. 2022 09; 100(3):313-319.
-
Iwamoto SJ, Rothman MS, Duan S, Baker JC, Mumm S, Whyte MP. Early-onset Paget's disease of bone in a Mexican family caused by a novel tandem duplication (77dup27) in TNFRSF11A that encodes RANK. Bone. 2020 04; 133:115224.
-
Mensah KA, Chen JW, Schickel JN, Isnardi I, Yamakawa N, Vega-Loza A, Anolik JH, Gatti RA, Gelfand EW, Montgomery RR, Horowitz MC, Craft JE, Meffre E. Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis. Sci Transl Med. 2019 11 20; 11(519).
-
Hai L, Szwarc MM, Lonard DM, Rajapakshe K, Perera D, Coarfa C, Ittmann M, Fernandez-Valdivia R, Lydon JP. Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland. Cytokine. 2019 11; 123:154745.
-
Yamagishi T, Kawashima H, Ogose A, Ariizumi T, Oike N, Sasaki T, Hatano H, Ohashi R, Umezu H, Ajioka Y, Endo N. Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors. Tohoku J Exp Med. 2019 06; 248(2):87-97.
-
Lloyd SA, Morony SE, Ferguson VL, Simske SJ, Stodieck LS, Warmington KS, Livingston EW, Lacey DL, Kostenuik PJ, Bateman TA. Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice. Bone. 2015 Dec; 81:562-572.
-
Szwarc MM, Kommagani R, Jacob AP, Dougall WC, Ittmann MM, Lydon JP. Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS One. 2015; 10(6):e0128467.
-
Sultana F, Rasool M. A novel therapeutic approach targeting rheumatoid arthritis by combined administration of morin, a dietary flavanol and non-steroidal anti-inflammatory drug indomethacin with reference to pro-inflammatory cytokines, inflammatory enzymes, RANKL and transcription factors. Chem Biol Interact. 2015 Mar 25; 230:58-70.
-
Shu L, Beier E, Sheu T, Zhang H, Zuscik MJ, Puzas EJ, Boyce BF, Mooney RA, Xing L. High-fat diet causes bone loss in young mice by promoting osteoclastogenesis through alteration of the bone marrow environment. Calcif Tissue Int. 2015 Apr; 96(4):313-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|